Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.…
Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 3.490 USD on 20 November 2026, down 86.3% over 52 weeks. Its 52-week range is 2.576 USD to 44.40 USD: the price is 92.1% below the high and 35.5% above the low.
Its market capitalisation is 16.63M USD.
Shuttle Pharmaceuticals Holdings reports an operating margin of 0.0%.
Its debt exceeds its cash by 104.92K USD, a debt-to-equity ratio of 0.10. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.